Page last updated: 2024-08-23

paroxetine and Acute Confusional Senile Dementia

paroxetine has been researched along with Acute Confusional Senile Dementia in 20 studies

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (15.00)18.2507
2000's10 (50.00)29.6817
2010's5 (25.00)24.3611
2020's2 (10.00)2.80

Authors

AuthorsStudies
Finsen, B; Gramsbergen, JB; Hasselstrøm, J; Lambertsen, KL; Metaxas, A; Olesen, LØ; Severino, M; Sivasaravanaparan, M; von Linstow, CU; Wiborg, O1
Ai, PH; Chen, S; Feng, DF; Liu, XD; Pan, YB; Sun, S; Xu, NJ; Zhu, XN1
Baroni, M; Boccardi, V; Ercolani, S; Giordano, M; Longo, A; Mecocci, P; Paolacci, L; Ruggiero, C1
Bouzinova, EV; Finsen, B; Hasselstrøm, JB; Olesen, LØ; Severino, M; Sivasaravanaparan, M; Wiborg, O1
Alexopoulos, GS1
Ellison, JM1
Bertoletti, E; Chilovi, BV; Conti, M; Padovani, A; Rozzini, L; Trabucchi, M; Zanetti, M1
Collins, A; Gragg, M; Sherrod, RA; Wynn, S1
Fang, Y; Jia, Y; Lian, Y; Wei, J; Xu, Y; Zeng, Z; Zhang, L; Zhao, X; Zhu, H1
Lebert, F1
Cahill, CM; Gullans, SR; Payton, S; Randall, JD; Rogers, JT1
Cuny, GD; Morse, LJ; Payton, SM; Rogers, JT1
Ahl, M; Bush, A; Huang, X; Rogers, JT; Tucker, S; Westaway, D1
Ahl, M; Bandyopadhyay, S; Bush, AI; Cho, HH; Cuny, GD; Goldstein, LE; Huang, X; Rogers, JT; Tucker, S; Westaway, D1
Brown, M; Clark, RF; Gray, AJ; Guo, Z; Halagappa, VM; Iyun, T; Martin, B; Matsuoka, Y; Mattson, MP; Maudsley, S; Nelson, RL; Pearson, M1
Bales, KR1
Reynolds, CF1
Burke, WJ; Dewan, V; Folks, DG; Nadolny, GC; Roccaforte, WH; Wengel, SP1
Cohen, CI; Trappler, B1
Bensasi, S; Houck, PR; Mazumdar, S; Miller, MD; Mulsant, BH; Nebes, R; Pollock, BG; Reynolds, CF; Stack, J; Sweet, RA1

Reviews

3 review(s) available for paroxetine and Acute Confusional Senile Dementia

ArticleYear
[Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias].
    Presse medicale (Paris, France : 1983), 2003, Jul-26, Volume: 32, Issue:25

    Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Dementia; Depression; Fluoxetine; Humans; Neuropsychological Tests; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Time Factors; Trazodone

2003
Paroxetine administration decreases AD-like pathology and reverses memory impairments in a transgenic model of Alzheimer disease.
    Experimental neurology, 2007, Volume: 207, Issue:1

    Topics: Alzheimer Disease; Animals; Disease Models, Animal; Memory; Memory Disorders; Mice; Paroxetine

2007
Depression: making the diagnosis and using SSRIs in the older patient.
    Geriatrics, 1996, Volume: 51, Issue:10

    Topics: 1-Naphthylamine; Adult; Aged; Alzheimer Disease; Depressive Disorder; Diagnosis, Differential; Dose-Response Relationship, Drug; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline

1996

Trials

2 trial(s) available for paroxetine and Acute Confusional Senile Dementia

ArticleYear
Use of SSRIs in "very old" depressed nursing home residents.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 1998,Winter, Volume: 6, Issue:1

    Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Alzheimer Disease; Central Nervous System Diseases; Dementia, Vascular; Depressive Disorder; Female; Fluoxetine; Homes for the Aged; Humans; Male; Matched-Pair Analysis; New York; Nursing Homes; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Statistics, Nonparametric

1998
A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2001,Fall, Volume: 9, Issue:4

    Topics: Aged; Alzheimer Disease; Antidepressive Agents, Tricyclic; Depression; Double-Blind Method; Female; Humans; Male; Nortriptyline; Paroxetine; Selective Serotonin Reuptake Inhibitors

2001

Other Studies

15 other study(ies) available for paroxetine and Acute Confusional Senile Dementia

ArticleYear
Efficacy of Chronic Paroxetine Treatment in Mitigating Amyloid Pathology and Microgliosis in APPSWE/PS1ΔE9 Transgenic Mice.
    Journal of Alzheimer's disease : JAD, 2022, Volume: 87, Issue:2

    Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Animals; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Paroxetine; Plaque, Amyloid; Presenilin-1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins

2022
Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice.
    Translational neurodegeneration, 2020, 05-12, Volume: 9, Issue:1

    Topics: Affective Symptoms; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Memory Disorders; Mice; Mice, Transgenic; Neuroprotective Agents; Paroxetine; Presenilin-1; Prodromal Symptoms; Receptors, N-Methyl-D-Aspartate; Selective Serotonin Reuptake Inhibitors; Time Factors

2020
Anticholinergic Burden and Functional Status in Older People with Cognitive Impairment: Results from the Regal Project.
    The journal of nutrition, health & aging, 2017, Volume: 21, Issue:4

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinergic Antagonists; Cognitive Dysfunction; Cross-Sectional Studies; Female; Hospitalization; Humans; Italy; Longitudinal Studies; Male; Memory; Outpatients; Paroxetine; Risperidone; Trazodone

2017
Behavioural Phenotyping of APPswe/PS1δE9 Mice: Age-Rrelated Changes and Effect of Long-Term Paroxetine Treatment.
    PloS one, 2016, Volume: 11, Issue:11

    Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cognition Disorders; Disease Models, Animal; Male; Maze Learning; Memory Disorders; Mice; Mice, Transgenic; Paroxetine; Presenilin-1; Social Behavior

2016
Personalizing the care of geriatric depression.
    The American journal of psychiatry, 2008, Volume: 165, Issue:7

    Topics: Aged; Alzheimer Disease; Antidepressive Agents, Tricyclic; Brain; Case Management; Comorbidity; Depressive Disorder, Major; Health Services for the Aged; Humans; Magnetic Resonance Imaging; Nortriptyline; Paroxetine; Patient-Centered Care; Psychology; Selective Serotonin Reuptake Inhibitors; Socioeconomic Factors

2008
A 60-year-old woman with mild memory impairment: review of mild cognitive impairment.
    JAMA, 2008, Oct-01, Volume: 300, Issue:13

    Topics: Aging; Alzheimer Disease; Cognition; Cognition Disorders; Counseling; Diagnosis, Differential; Diet; Female; Humans; Life Style; Magnetic Resonance Imaging; Memory Disorders; Middle Aged; Neurotransmitter Agents; Paroxetine; Positron-Emission Tomography; Psychotropic Drugs; Risk Factors

2008
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
    International psychogeriatrics, 2010, Volume: 22, Issue:1

    Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Movement Disorders; Neuropsychological Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index

2010
Dissecting dementia, depression, and drug effects in older adults.
    Journal of psychosocial nursing and mental health services, 2010, Volume: 48, Issue:1

    Topics: Aged; Alzheimer Disease; Antidepressive Agents; Depressive Disorder; Diagnosis, Differential; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Nootropic Agents; Nursing Diagnosis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Substance Withdrawal Syndrome

2010
BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response.
    Journal of Alzheimer's disease : JAD, 2011, Volume: 26, Issue:3

    Topics: Aged; Alleles; Alzheimer Disease; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Depression; Female; Genotype; Humans; Linkage Disequilibrium; Male; Paroxetine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2011
Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol.
    Journal of molecular neuroscience : MN, 2003, Volume: 20, Issue:3

    Topics: 5' Untranslated Regions; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anti-Bacterial Agents; Azithromycin; Cell Line, Tumor; Chelating Agents; Dimercaprol; Drug Evaluation, Preclinical; Genes, Reporter; Humans; Luciferases; Paroxetine; Protein Synthesis Inhibitors; RNA, Messenger; Selective Serotonin Reuptake Inhibitors

2003
FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein.
    Journal of molecular neuroscience : MN, 2004, Volume: 24, Issue:1

    Topics: 5' Untranslated Regions; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Line, Tumor; Chelating Agents; Dimercaprol; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Epithelial Cells; Humans; Iron; Neuroprotective Agents; Organometallic Compounds; Paroxetine; Protein Biosynthesis; Protein Processing, Post-Translational; Protein Synthesis Inhibitors; Receptors, Transferrin; RNA, Messenger

2004
Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5' untranslated region.
    Current Alzheimer research, 2005, Volume: 2, Issue:2

    Topics: 5' Untranslated Regions; Acetylcysteine; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Drug Approval; Drugs, Investigational; Erythromycin; Mice; Mice, Transgenic; Paroxetine; Pilot Projects

2005
RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine.
    Current Alzheimer research, 2006, Volume: 3, Issue:3

    Topics: 5' Untranslated Regions; Acetylcysteine; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Drug Evaluation, Preclinical; Drugs, Investigational; Erythromycin; Mice; Mice, Transgenic; Paroxetine; Peptide Fragments; Pilot Projects; Protein Biosynthesis; Protein Synthesis Inhibitors; RNA, Messenger

2006
Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice.
    Experimental neurology, 2007, Volume: 205, Issue:1

    Topics: Alzheimer Disease; Amygdala; Amyloid beta-Peptides; Animals; Avoidance Learning; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Female; Hippocampus; Male; Maze Learning; Mental Disorders; Mice; Mice, Transgenic; Motor Activity; Paroxetine; Peptide Fragments; Selective Serotonin Reuptake Inhibitors; Swimming; Tauopathies

2007
The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia.
    International journal of geriatric psychiatry, 1997, Volume: 12, Issue:5

    Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Depressive Disorder; Female; Humans; Male; Paroxetine; Psychotic Disorders; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline

1997